CN116113429A - 新型多肽及其治疗用途 - Google Patents

新型多肽及其治疗用途 Download PDF

Info

Publication number
CN116113429A
CN116113429A CN202180048716.7A CN202180048716A CN116113429A CN 116113429 A CN116113429 A CN 116113429A CN 202180048716 A CN202180048716 A CN 202180048716A CN 116113429 A CN116113429 A CN 116113429A
Authority
CN
China
Prior art keywords
compound
formula
peptide
preceding aspects
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180048716.7A
Other languages
English (en)
Inventor
韩捷
沈志超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hong Xu Biological Medicine Science And Technology Beijing Co ltd
Original Assignee
Hong Xu Biological Medicine Science And Technology Beijing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Xu Biological Medicine Science And Technology Beijing Co ltd filed Critical Hong Xu Biological Medicine Science And Technology Beijing Co ltd
Publication of CN116113429A publication Critical patent/CN116113429A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及多肽化学领域，具体而言本发明涉及一种多肽化合物及其在医疗中的用途。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180048716.7A 2020-07-06 2021-07-06 新型多肽及其治疗用途 Pending CN116113429A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010643549 2020-07-06
CN2020106435498 2020-07-06
PCT/CN2021/104805 WO2022007805A1 (zh) 2020-07-06 2021-07-06 新型多肽及其治疗用途

Publications (1)

Publication Number Publication Date
CN116113429A true CN116113429A (zh) 2023-05-12

Family

ID=79552781

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180048716.7A Pending CN116113429A (zh) 2020-07-06 2021-07-06 新型多肽及其治疗用途

Country Status (6)

Country Link
US (1) US20230263896A1 (zh)
EP (1) EP4177263A1 (zh)
CN (1) CN116113429A (zh)
AU (1) AU2021304762B2 (zh)
CA (1) CA3185229A1 (zh)
WO (1) WO2022007805A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022210988B9 (en) 2021-01-20 2024-02-22 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US8507428B2 (en) * 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
WO2014096150A1 (en) * 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
EP3080154B1 (en) * 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) * 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080152A1 (en) * 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
AU2019391300A1 (en) * 2018-12-03 2021-07-01 Antag Therapeutics Aps Modified gip peptide analogues
CA3125774A1 (en) * 2019-01-07 2020-07-16 Vitalixir (Beijing) Co., Ltd Novel peptides and their therapeutic applications

Also Published As

Publication number Publication date
CA3185229A1 (en) 2022-01-13
AU2021304762A1 (en) 2023-03-09
US20230263896A1 (en) 2023-08-24
AU2021304762B2 (en) 2024-05-02
EP4177263A1 (en) 2023-05-10
WO2022007805A1 (zh) 2022-01-13

Similar Documents

Publication Publication Date Title
EP1934245B1 (en) Y2 selective receptor agonists for therapeutic interventions
JP7324530B2 (ja) 新型ポリペプチド及びその治療用途
RU2383553C2 (ru) Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r)
KR100593348B1 (ko) 글루카곤-유사 펩티드-1 유사체
CN108026153B (zh) 作为选择性肽双重glp-1/胰高血糖素受体激动剂的新毒蜥外泌肽-4衍生物
CN106928341B (zh) 定点单取代聚乙二醇化Exendin类似物及其制备方法
CN112074531A (zh) Gip衍生物及其用途
KR20180004276A (ko) 글루카곤 및 glp-1 공-효능제 화합물
WO2013170636A1 (zh) 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
EP1786458A2 (en) Y2/y4 selective receptor agonists for therapeutic interventions
CN113493504A (zh) GIP-Exendin-4嵌合肽的分子改构及其二聚体在治疗糖尿病中的应用
MX2011008774A (es) Conjugados citotoxicos que tienen un compuesto de unión de receptores de neuropeptidos y.
US20080214440A1 (en) Vasoactive intestinal polypeptide compositions
JP2022551233A (ja) 異なる構造のｇｌｐ－１アナログペプチド修飾二量体およびその調製方法のｉｉ型糖尿病の治療における用途
WO2022007809A1 (zh) 新型多肽制剂及其治疗用途
WO2020103729A1 (zh) 胰高血糖素衍生肽及其用途
WO2022007805A1 (zh) 新型多肽及其治疗用途
US20090099074A1 (en) Modulating food intake
EP1608680A2 (en) Glp-2 derivatives
CN114891071A (zh) 新型多肽及其治疗用途
CN112608378A (zh) 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用
CN116650424A (zh) 新型多肽制剂及其治疗用途
WO2024098718A1 (zh) 一种新型长效多肽化合物、组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination